The disclosure provides new methods for treatment of inflammatory and autoimmune diseases including diseases of impaired glucose homeostasis and includes the usage oral usage immunotherapies that are T lymphocyte helper cell 17 (Th17)-inhibitors and usage is based on the patient's gut microbiome to determine if they are at risk for targeted organ(s) attack by Th17. The delivery of Th17-inhibitors is delivered preferably orally because Th17 lines the mucosa of the gastrointestinal tract. With the treatment of Type 1 diabetes, both a Th17-inhibitor is used with existing or new islet neogenesis agents presented within.
